Navigation Links
Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
Date:3/17/2008

Clinical study to commence late this year

MELBOURNE, Australia, March 17 /PRNewswire/ -- Cytopia Limited (ASX: CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease.

Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) that affect over 150,000 patients in the USA and more than twice that worldwide. Over 95% of PV cases and over 50% of ET and primary and secondary myelofibrosis cases are believed to be caused by a mutation in the JAK2 kinase enzyme. This renders the kinase permanently active and leads to the overproduction of particular blood cells.

No specific treatments exist for these diseases and untreated progressive disease can lead to leukemia or myelofibrosis. CYT387 possesses an excellent selectivity profile against a large panel of kinases and other pharmacological targets. It also has excellent pharmacokinetics including oral bioavailability and in preclinical models has a promising safety profile.

CYT387 has also recently shown efficacy in a well-validated in-vivo model of myeloproliferative disorders in studies in the laboratory of physician- scientist Michael Deininger MD PhD at Oregon Health & Science University Cancer Institute, USA. Results showed a profound effects on abnormal blood counts and clinical symptoms of MPDs in mice that were dosed orally.

Dr Deininger said, "We are highly encouraged by Cytopia's compound in this model of myeloproliferative disease which clearly indicates significant improvement of symptoms and disease remission. The favorable data from this animal model augers well for activity of the compound in the clinic."

The compound will now be progres
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
2. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
3. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
4. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
5. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
6. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
7. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
8. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
9. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
10. New Clinical Studies Presented at the 14th World Congress of Anesthesiology Demonstrate Masimo Advancements in Patient Care
11. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... SCOLR Pharma, Inc. (Amex...three and nine months ended September 30, 2009. ...and CEO, said, "We continue to advance discussions...ation. Several potential partners have committed s...al resources as they evaluate the potential commer...
(Date:11/6/2009)...wswire-FirstCall/ -- Recession in domestic and int...Allied Healthcare Products in the first quarter of... Sales declines pushed Allied into a loss for the ...745,000, or negative 9 cents per share, compared t... or 3 cents per share. ,, Sales fell about 21 ...
(Date:11/6/2009)... 6 DUSA Pharmaceuticals,...pany that is developing and marketing Levulan(...focused on patients with common skin conditions, a...tive Officer, will present a corporate overview at...Tuesday, November 10, 2009 at 10:00 a.m. ET at the...
Breaking Medicine Technology:SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 2SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 3SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 4SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 5SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 6SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 7SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 8SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results 9Recession Continues to Depress Sales at Allied Healthcare Products 2Recession Continues to Depress Sales at Allied Healthcare Products 3Recession Continues to Depress Sales at Allied Healthcare Products 4Recession Continues to Depress Sales at Allied Healthcare Products 5Recession Continues to Depress Sales at Allied Healthcare Products 6VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ 5420 1VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ 5420 2VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ 5420 3VIA Pharmaceuticals Receives Favorable Hearing Decision From NASDAQ 5420 4New old drug fights colon cancer 59359 1New old drug fights colon cancer 59359 2NIH awards more than 2454 Million to Kaiser Permanente to conduct health research 59355 1NIH awards more than 2454 Million to Kaiser Permanente to conduct health research 59355 2
...udies examining the effects of stem cell source an...s will be explored at a press conference taking pl...e 50th Annual Meeting of the American Society of H...s from a study examining a specialized technique f...lood for transplantation will also be shared durin...
...y assessing the quality of care for patients with ...ngs will be presented at a press conference on Sat...nnual Meeting of the American Society of Hematolog...ning methods that help determine stroke risk in ch...y examining the effects of long-term hydroxyurea u...
Other Medicine Technology:Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes 2Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes 3Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes 4Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes 5Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes 6Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes 7Research Explores the Effects of Stem Cell Source and Patient Age on Stem Cell Transplantation Outcomes 8Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 2Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 3Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 4Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 5Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 6Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 7Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 8Studies Examine Quality of Care for Hospitalized Sickle Cell Disease Patients and Effective Methods for Detecting Risk of Stroke in Children With This Disorder 9
(Date:11/8/2009)...PRNewswire-USNewswire/ -- Speaker Nancy Pelosi and...ing the House passage of H.R. 3962, the Affordable...a vote of 220 to 215. Below are the Speaker,s ope...just received a call from the President of the Uni...reat victory for the American people. I thank the ...
(Date:11/8/2009)...3D Global Solutions is pleased to announce that it...sal effort for ReSound who recently received an aw...tract. The award includes not only the Veterans Ad...nd other federal agencies. , ...obal Solutions is pleased to announce that it has ...
(Date:11/8/2009)...A jury of 8 people in the Western District of Penn...n pain and suffering for a medical malpractice cas...icia Nocera of Thomas E. Crenney and Associates, L...ta Monestersky and against the Uniontown Hospital....al hysterectomy at age 18. , ...
(Date:11/8/2009)...twork of Hispanic health advocates committed to ac..., WASHINGTON, Nov. 7 "...hey have heard the voice of America,s families by .... Now the Senate must deliver, without delay, on t... Dr. Jane L. Delgado, President and CEO of the Nat...
(Date:11/8/2009)...sage of H.R. 3961 to Secure the Stability of Medic... -- Statement Attributable to: J. James Rohack, M.... (Logo: http://www.newscom.com/cgi-bin/prnh/2008...of the House health reform bill, which will help i...ns and calls for swift passage of H.R. 3961 to sec...
Breaking Medicine News(10 mins):Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2
...gh School Raises More than $17,000 and Beats S... Cystic Fibrosis Foundation announced today that C...it Vestavia Hills High School in Birmingham, Ala.,...,000 for the CureFinders (R) program for the 20...
...Ovarian Cancer Coalition Says Gynecologic Health E... Factors , , DALLAS, May 5 At Mother,s Day, a ne...n (NOCC), www.ovarian.org , reveals some startl...g or skipping their annual gynecological exams alt...
...Experienced Law Firm Provides Informational Resour... Houston, TX (PRWEB) May 5, 2009 -- In res... loss products, Williams Kherkher has taken action...each efforts, it has launched an online resource c...
...May 5 Increased public and private expenditure on...ical insurance coverage and continued foreign dono...or growth within the Kenyan healthcare industry. T...enforcement. , , (Logo: http://www.newscom.com/...
...Sweden Tops List, Niger Ranks Last, United States ... Westport, Conn. (Vocus) May 5, 2009 -...es to be a mother, while sub-Saharan African count...organization,s State of the World,s Mothers 2009 ...
...prescription supply for $10 via free mail delivery... , , BENTONVILLE, Ark., May 5 Today in Michigan...r a 90-day supply of 300 generic prescriptions, ea...age of this new affordable pharmacy program from W...
Other Medicine News:Health News:CW's 7th Heaven Actress Mackenzie Rosman to Visit Birmingham Area High School to Honor Cystic Fibrosis Foundation Fundraising 2Health News:Women's Gynecological Exams: Another Victim of the Troubled Economy? 2Health News:Williams Kherkher Warns of Liver Damage, Failure from Hydroxycut 2Health News:Higher Outlays and Improved Regulatory Enforcement Create Opportunities in the Kenyan Healthcare Industry, Reveals Frost & Sullivan 2Health News:Higher Outlays and Improved Regulatory Enforcement Create Opportunities in the Kenyan Healthcare Industry, Reveals Frost & Sullivan 3Health News:A Mother's Report Card: The Best - and Worst - Countries for Mothers 2Health News:A Mother's Report Card: The Best - and Worst - Countries for Mothers 3Health News:New Walmart Program Broadens Access to Affordable Prescriptions in Michigan 2Health News:New Walmart Program Broadens Access to Affordable Prescriptions in Michigan 3
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: